CHARLES OF THE COLUMN TO THE C Serial No

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CIPATION

IN AN APPLICATION

Atty. Docket No. X-13134

10/018,377

MAY 2 9 2002

Applicant(s) Michael Rosario DeFelippis, et al.

Filing Date December 18, 2001 Group 1614

U.S. PATENT DOCUMENTS

<del></del>		* * * * * * * * * * * * * * * * * * * *	IS INDIV				
Examiner Initial		Document Number	704 nFDate	Name	Class	Sub- class	Filing Date
RT	AA	3,864,325	Feb. 4, 1975	Smyth	260	112.7	Appropriate Nov. 13, 197
1	AB	3,907,763	Sep. 23, 1975	Brandenberg, et al.	260	112.7	Feb. 16, 197
	AC	3,950,517	Apr. 13, 1976	Lindsay, et al.	424	178	Dec. 6, 1974
	AD	4,701,440	Oct. 20, 1987	Grau	514	3	Jun. 06, 198
	AE	5,506,203	Apr. 09, 1996	Backstrom, et al.	514	4	Jun. 23, 199
	AF	5,658,878	Aug. 19, 1997	Backstrom, et al.	514	3	Jun. 6, 1995
	AG	5,693,609	Dec. 02, 1997	Baker, et al.	514	3	Nov. 17, 199
	АН	5,700,904	Dec. 23, 1997	Baker, et al.	530	305	Jun. 7, 1995
	AI	5,898,028	Apr. 27, 1999	Jensen, et al.	514	4	Mar. 20, 199
	AJ	5,922,675	Jul. 13, 1999	Baker, et al.	514	4	Nov. 26, 199
	AK	6,051,551	Apr. 18, 2000	Hughes, et al.	514	3	Oct. 29, 199
	AL	6,268,335	Jul. 31, 2001	Brader	514	3	Oct. 22, 199
	AM	6,310,038	Oct. 30, 2001	Havelund	514	4	Mar. 20, 199
	AN	6,335,316	Jan. 1, 2002	Hughes, et al.	514	3	Mar. 10, 200
	AO	2001/0039260	Nov. 8, 2001	Havelund	514	4	Apr. 17, 200
	AP	2001/0041786	Nov. 15, 2001	Brader, et al.	530	300	Jun. 7, 1995
XAMINER				DATE CONSIDERED			

R. Teller 7/2/03 \*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO 1449 (modified) Atty. Docket No. Serial No 10/018,377 X-13134 TPE information disclosure of Ation Applicant(s) IN AN APPLICATION Michael Rosario DeFelippis, et al. Filing Date Group 2 9 2002 December 18, 2001 1614 FOREIGN PATENT DOCUMENTS Date Document Number Country Class Sub-Translation class yes no EP 0646379 04May95 ΕP RT BB EP 0911035 28Apr99 EΡ BC EP 0919242 02Jun99 EP EP 0951910 BD 270ct99 EP WO 95/07931 BE 23Mar95 WIPO WO 95/24183 14Sep95 WIPO BG WO 96/32149 170ct96 WIPO вн WO 98/31346 23Jul98 WIPO WO 98/33480 WIPO BI 06Aug98 WO 98/42367 WIPO ВJ 010ct98 WO 98/42368 010ct98 WIPO WO 98/42749 WIPO BL 010ct98 WO 99/21573 WIPO BM 06May99 BN WO 99/21578 06May99 WIPO BO WO 99/22754 14May99 WIPO WO 99/32116 WIPO BP 01Jul99 WO 00/43034 WIPO 27Jul00 BO BR WO 00/64940 02Nov00 WIPO WO 01/00674 04Jan01 WIPO BT WO 01/00675 04Jan01 WIPO

EXAMINER

R. Teller

DATE CONSIDERED

7/2/03

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

INFORMATION DISCLOSURE CYMPTON  Applicant(s)  While a company of the company of t	FORM PTO	) 1449 (ı	modified)	Atty. Docket No.	Serial No	40					
Brange, Jens, "Galenics of Insulin", Novo Research Institute, pp. 1- 103, Springer-Verlag, Berlin, Germany 1987.  CB Byron, P. R. and Patton, J. S., "Drug Delivery via the Respiratory Tract", J. Aerosol Medicine, 7(1):49-75, Mary Ann Liebert, Inc., 1994.  CC Edwards, et al., "Recent advances in pulmonary drug delivery using large, porous inhaled particles", J. Appl. Physiol. 84(2):379-385, the American Physiological Society, 1998.  CD Edwards, D. A., et al., "Large Porous Patticles for Pulmonary Drug Delivery", Science, 276:1863-1871, American Assos. Advancement Science, 1997.  CE Laube, et al., "Proving the Efficacy of Insulin Delivered Through the Lungs as an Aerosol", J. Biopharm. Sci., 3(1/2):162-169, St. Cosmas-Damian Scientific, 1992.  CF Niven, R., "Delivery of Biotherapeutics by Inhalation Aerosol", Crit. Rev. in Therapeutic Drug Carrier Systems, 12(23):151-231, Begell House, Inc., 1995.  CG Patton, J., Bukar, J., and Najarajan, S., "Inhaled insulin", Adv. Drug Delivery Rev., 35:235-247, Elsevier Science, 1999.  CH Patton, J. S. and Platz, R. M., "Aerosol Insulin A Brief Review", Respiratory Drug Delivery IV, pages 65-74, Interpharm Press, 1994.  CI Richards, Jane P., et al., "Preparation of a Microcrystalline Suspension Formulation of Typs2pPro29-Human Insulin with Ultralente Properties", Journal of Pharmaceutical Sciences, 88(9):861-867, American Chemical Society and American Pharmaceutical Association, September 1999.  CX Wahever, Rita, et al., "Sustained Release of Insulin From Insoluble Inhaled Particles", Drug Development Research 48:178-185, Wiley-Lies, Inc., 1999.  CX Whittingham, J. L., et al., "Crystal Structure of a Prolonged-Acting Insulin with Albumin-binding Properties", Biochemistry 36(10):2826-2831, American Chemical Society, 1997.  CL U.S. Patent Application Serial No. 09/491,253 (11 pages).  CM Pending claims for U.S. Application 09/980,962 (4 pages).  CN Pending claims for U.S. Application 09/980,962 (4 pages).	TNEODMAG	ידראז הדכי	CLOCUDE CLABETON	X-13134	10/018,377	ZM					
Brange, Jens, "Galenics of Insulin", Novo Research Institute, pp. 1- 103, Springer-Verlag, Berlin, Germany 1987.  CB Byron, P. R. and Fatton, J. S., "Drug Delivery via the Respiratory Tract", J. Aerosol Medicine, 7(1):49-75, Mary Ann Liebett, Inc., 1994.  CC Edwards, et al., "Recent advances in pulmonary drug delivery using large, porous inhaled particles", J. Appl. Physiol. 84(2):379-385, the American Physiological Society, 1998.  CD Edwards, D. A., et al., "Large Porous Particles for Pulmonary Drug Delivery", Science, 276:1663-1871, American Assos. Advancement Science, 1997.  CE Laube, et al., "Proving the Efficacy of Insulin Delivered Through the Lungs as an Aerosol", J. Biopharm. Sci., 3(1/2):163-169, St. Cosmas-Damian Scientific, 1992.  CF Niven, R., "Delivery of Biotherapeutics by Inhalation Aerosol", Crift. Rev. in Therapeutic Drug Carrier Systems, 12(23):151-231, Begell House, Inc., 1995.  CG Patton, J., Bubar, J., and Najarajan, S., "Inhaled insulin", Adv. Drug Delivery Rev., 35:235-247, Elsevier Science, 1999.  CH Patton, J. S. and Platz, R. M., "Aerosol Insulin A Brief Review", Respiratory Drug Delivery IV, pages 65-74, Interpharm Press, 1994.  CI Richards, Jane P., et al., "Preparation of a Microcrystalline Suspension Formulation of Lys22P70E99-Human Insulin with Ultralente Properties", Journal of Pharmaceutical Sciences, 88(9):861-867, American Chemical Society and American Pharmaceutical Association, September 1999.  CX Wahever, Rita, et al., "Sustained Release of Insulin From Insoluble Inhaled Particles", Drug Development Research 48:178-185, Wiley-Liss, Inc., 1999.  CK Pattingham, J. L., et al., "Crystal Structure of a Prolonged-Acting Insulin with Albumin-binding Properties", Biochemistry 36(10):2826-2831, American Chemical Society, 1997.  CL U.S. Patent Application Serial No. 09/491,253 (11 pages).  CM Pending claims for U.S. Application 09/980,962 (4 pages).  CN Pending claims for U.S. Application 09/980,962 (4 pages).					elinnis et al						
CA Brange, "Galenics of Insulin", Novo Research Institute, pp. 1- 103, Springer-Verlag, Berlin, Germany 1987.  CB Byron, P. R. and Fatton, J. S., "Drug Delivery via the Respiratory Tract", J. Aerosol Medicine, 7(1):49-75, Mary Ann Liebert, Inc., 1994.  CC Edwards, et al., "Recent advances in pulmonary drug delivery using large, porous inhaled particles", J. Appl. Physiol. 84(2):379-385, the American Physiological Society, 1998.  CD Edwards, D. A., et al., "Large Porous Particles for Pulmonary Drug Delivery", Science, 276:1686-1871, American Assos. Advancement Science, 1997.  CR Laube, et al., "Proving the Efficacy of Insulin Delivered Through the Lungs as an Aerosol", J. Biopharm. Sci, 3(1/2):163-169, St. Cosmas-Damian Scientific, 1992.  CF Niven, R., "Delivery of Biotherapeutics by Inhalation Aerosol", Crift. Rev. in Therapeutic Drug Carrier Systems, 12(243):151-231, Begell House, Inc., 1995.  CG Patton, J., Subar, J., and Najarajan, S., "Inhaled insulin", Adv. Drug Delivery Rev., 35:235-247, Elsevier Science, 1999.  CH Patton, J. S. and Platz, R. M., "Aerosol Insulin A Brief Review", Respiratory Drug Delivery IV, pages 65-74, Interpharm Press, 1994.  CI Richards, Jane P., et al., "Preparation of a Microcrystalline Suspension Formulation of Lys22ProE39-Human Insulin with Ultralente Properties", Journal of Pharmaceutical Sciences, 88(9):861-867, American Chemical Society and American Pharmaceutical Association, September 1999.  CX Winteringham, J. L., et al., "Sustained Release of Insulin From Insoluble Inhaled Particles", Drug Development Research 48:178-185, Wiley-Lies, Inc., 1999.  CK Wintingham, J. L., et al., "Crystal Structure of a Prolonged-Acting Insulin with Albumin-binding Properties", Biochemistry 36(10):2826-2831, American Chemical Society, 1997.  CL D. Pending claims for U.S. Application 09/958,536 (6 pages).  CM Pending claims for U.S. Application 09/958,536 (6 pages).			2 9 20	02 Wiling Date	Group	T 1					
Brange, Jens, "Galenics of Insulin", Novo Research Institute, pp. 1- 103, Springer-Verlag, Berlin, Germany 1987.  CB Byron, P. R. and Fatton, J. S., "Drug Delivery via the Respiratory Tract", J. Aerosol Medicine, 7(1):49-75, Mary Ann Liebett, Inc., 1994.  CC Edwards, et al., "Recent advances in pulmonary drug delivery using large, porous inhaled particles", J. Appl. Physiol. 84(2):379-385, the American Physiological Society, 1998.  CD Edwards, D. A., et al., "Large Porous Particles for Pulmonary Drug Delivery", Science, 276:1686-1871, American Assos. Advancement Science, 1997.  CE Laube, et al., "Proving the Efficacy of Insulin Delivered Through the Lungs as an Aerosol", J. Biopharm. Sci., 3(1/2):163-169, St. Cosmas-Damian Scientific, 1992.  CF Niven, R., "Delivery of Biotherapeutics by Inhalation Aerosol", Crit. Rev. in Therapeutic Drug Carrier Systems, 12(243):151-231, Begell House, Inc., 1995.  CG Patton, J., BuNar, J., and Najarajan, S., "Inhaled insulin", Adv. Drug Delivery Rev., 35:235-247, Elsevier Science, 1999.  CH Patton, J. S. and Platz, R. M., "Aerosol Insulin A Brief Review", Respiratory Drug Delivery IV, pages 65-74, Interpharm Press, 1994.  CI Richards, Jane P., et al., "Preparation of a Microcrystalline Suspension Formulation of Lys22970629-Human Insulin with Ultralente Properties", Journal of Pharmaceutical Sciences, 88(9):861-867, American Chemical Society and American Pharmaceutical Association, September 1999.  CX Wahever, Rita, et al., "Sustained Release of Insulin From Insoluble Inhaled Particles", Drug Development Research 48:178-185, Wiley-Lies, Inc., 1999.  CK Pattent Application Serial No. 09/491,253 (11 pages).  CM Pending claims for U.S. Application 09/980,962 (4 pages).  CM Pending claims for U.S. Application 09/980,962 (4 pages).  CM Pending claims for U.S. Application 09/980,962 (4 pages).			MAY 1 3 20	December 18, 2001	1614	白色					
CA Brange, "Galenics of Insulin", Novo Research Institute, pp. 1- 103, Springer-Verlag, Berlin, Germany 1987.  CB Byron, P. R. and Fatton, J. S., "Drug Delivery via the Respiratory Tract", J. Aerosol Medicine, 7(1):49-75, Mary Ann Liebert, Inc., 1994.  CC Edwards, et al., "Recent advances in pulmonary drug delivery using large, porous inhaled particles", J. Appl. Physiol. 84(2):379-385, the American Physiological Society, 1998.  CD Edwards, D. A., et al., "Large Porous Particles for Pulmonary Drug Delivery", Science, 276:1686-1871, American Assos. Advancement Science, 1997.  CR Laube, et al., "Proving the Efficacy of Insulin Delivered Through the Lungs as an Aerosol", J. Biopharm. Sci, 3(1/2):163-169, St. Cosmas-Damian Scientific, 1992.  CF Niven, R., "Delivery of Biotherapeutics by Inhalation Aerosol", Crift. Rev. in Therapeutic Drug Carrier Systems, 12(243):151-231, Begell House, Inc., 1995.  CG Patton, J., Subar, J., and Najarajan, S., "Inhaled insulin", Adv. Drug Delivery Rev., 35:235-247, Elsevier Science, 1999.  CH Patton, J. S. and Platz, R. M., "Aerosol Insulin A Brief Review", Respiratory Drug Delivery IV, pages 65-74, Interpharm Press, 1994.  CI Richards, Jane P., et al., "Preparation of a Microcrystalline Suspension Formulation of Lys22ProE39-Human Insulin with Ultralente Properties", Journal of Pharmaceutical Sciences, 88(9):861-867, American Chemical Society and American Pharmaceutical Association, September 1999.  CX Winteringham, J. L., et al., "Sustained Release of Insulin From Insoluble Inhaled Particles", Drug Development Research 48:178-185, Wiley-Lies, Inc., 1999.  CK Wintingham, J. L., et al., "Crystal Structure of a Prolonged-Acting Insulin with Albumin-binding Properties", Biochemistry 36(10):2826-2831, American Chemical Society, 1997.  CL D. Pending claims for U.S. Application 09/958,536 (6 pages).  CM Pending claims for U.S. Application 09/958,536 (6 pages).			E.	OTHER DOCUMENTS		93					
Brange, Jens, "Galenics of Insulin", Novo Research Institute, pp. 1- 103, Springer-Verlag, Berlin, Germany 1987.  CB Byron, P. R. and Patton, J. S., "Drug Delivery via the Respiratory Tract", J. Aerosol Medicine, 7(1):49-75, Mary Ann Liebert, Inc., 1994.  CC Edwards, et al., "Recent advances in pulmonary drug delivery using large, porous inhaled particles", J. Appl. Physiol. 84(2):379-385, the Aerosol Medicine, 7(1):49-75, Mary Ann Liebert, Inc., 1994.  CD Edwards, D. A., et al., "Large Porous Particles for Pulmonary Drug Delactery", Science, 276:1866-1871, American Assos. Advancement Science, 1997.  CE Laube, et al., "Proving the Efficacy of Insulin Delivered Through the Lungs as an Aerosol", J. Biopharm. Sci., 3(1/2):163-95, St. Cosmas-Damian Scientific, 1992.  CF Naven, R., "Delivery of Biotherapeutics by Inhalation Aerosol", Crit. Rev. in Therapeutic Drug Carrier Systems, 12(243):151-231, Begell House, Inc., 1995.  CG Patton, J., Bukar, J., and Najarajan, S., "Inhaled insulin", Adv. Drug Delivery Rev., 35:235-247, Ilsevier Science, 1999.  CH Patton, J. S. and Platz, R. M., "Aerosol Insulin. A Brief Review", Respiratory Drug Delivery Rev., 35:235-247, Ilsevier Science, 1999.  CH Richards, Jane P., et al., "Preparation of a Microcrystalline Suspension Formulation of Lys28Pro829-Human Insulin with Ultralente Properties", Journal of Pharmaceutical Science, 88(9):861-867, American Chemical Society and American Pharmaceutical Association, September 1999.  CJ Vanhever, Rita, et al., "Sustained Release of Insulin From Insoluble Inhaled Particles", Drug Development Research 48:178-188, Wiley-Liss, Minterland Science, 1999.  CK Whittingam, J. L., et al., "Crystal Structure of a Prolonged-Acting Insulin with Albumin-binding Properties", Biochemistry 36(10):2826-2811, American Chemical Science, 1997.  CM Pending claims for U.S. Application 09/980,962 (4 pages).  CM Pending claims for U.S. Application 09/980,962 (4 pages).		· · · · · · · · · · · · · · · · · · ·	TOANEN!	int		<b>'</b>					
CB Byron, P. R. and Fatton, J. S., "Drug Delivery via the Respiratory Tract", J. Aerosol Medicine, 7(1):49-75, Mary Ann Libert, Inc., 1994.  CC Edwards, et al., "Recent advances in pulmonary drug delivery using large, porous inhaled particles", J. Appl. Physiol. 84(2):379-385, the American Physiological Society, 1998.  CD Edwards, D. A., et al., "Large Porous Particles for Pulmonary Drug Delivery", Science, 276:1868-1871, American Assos. Advancement Science, 1997.  CE Laube, et al., "Proving the Efficacy of Insulin Delivered Through the Lungs as an Aerosol", J. Biopharm. Sci., 3(1/2):163-169, St. Cosmas-Damian Scientific, 1992.  CF Niven, R., "Delivery of Biotherapeutics by Inhalation Aerosol", Crit. Rev. in Therapeutic Drug Carrier Systems, 12(2k3):151-231, Begell House, Inc., 1995.  CG Patton, J., Bukar, J., and Najarajan, S., "Inhaled insulin", Adv. Drug Delivery Rev., 35:235-247, Elsevier Science, 1999.  CH Patton, J. S. and Platz, R. M., "Aerosol Insulin A Brief Review", Respiratory Drug Delivery IV, pages 65-74, Interpharm Press, 1994.  CI Richards, Jane P., et al., "Preparation of a Microcrystalline Suspension Formulation of Lyss2PhroB29-Human Insulin with Ultralente Properties", Journal of Pharmaceutical Sciences, 88(9):861-867, American Chemical Society and American Pharmaceutical Association, September 1999.  CK Winttingham, J. L., et al., "Sustained Release of Insulin From Insoluble Inhaled Particles", Drug Development Research 48:178-185, Wiley-Liss, Inc., 1993.  CK Pending claims for U.S. Applications 09/491,253 (11 pages).  CN Pending claims for U.S. Application 09/980,962 (4 pages).  CN Pending claims for U.S. Application 09/980,962 (4 pages).  CN Pending claims for U.S. Application 09/980,962 (4 pages).	24	CA	Brange, Jens, "Ga	llenics of Insulin", Novo	Research Institute	e, pp. 1-					
Tract", J. Aerosol Medicine, 7(1):49-75, Mary Ann Liebert, Inc., 1994.  CC  CC  CC  CC  CC  CC  CC  CC  CC		CB		<del>-</del>							
large, porous inhaled particles", J. Appl. Physiol. 84(2):379-385, the American Physiological Society, 1998.   CD   Edwards, D. A., et al., "Large Porous Particles for Pulmonary Drug Delivery", Science, 276:1868-1871, American Assos. Advancement Science, 1997.   CE   Laube, et al., "Proving the Efficacy of Insulin Delivered Through the Lungs as an Aerosol", J. Biopharm. Sci, 3(1/2):163-169, St. Cosmas-Damian Scientific, 1992.   CF   Niven, R., "Delivery of Biotherapeutics by Inhalation Aerosol", Crit. Rev. in Therapeutic Drug Carrier Systems, 12(243):151-231, Begell House, Inc., 1995.   CG   Patton, J., Bukar, J., and Najarajan, S., "Inhaled insulin", Adv. Drug Delivery Rev., 35:235-247, Elsevier Science, 1999.   CH   Patton, J. S. and Platz, R. M., "Aerosol Insulin- A Brief Review", Respiratory Drug Delivery IV, pages 65-74, Interpharm Press, 1994.   CI   Richards, Jane P., et al., "Preparation of a Microcrystalline Suspension Formulation of LyseB287cb29-Human Insulin with Ultralente Properties", Journal of Pharmaceutical Sciences, 88(9):861-867, American Chemical Society and American Pharmaceutical Association, September 1999.   CJ   Vanbever, Rita, et al., "Sustained Release of Insulin From Insoluble Inhaled Particles", Drug Development Research 48:178-185, Wiley-Liss, Inc., 1999.   CK   Whittingham, J. L., et al., "Crystal Structure of a Prolonged-Acting Insulin with Albumin-binding Properties", Biochemistry 36(10):2826-2831, American Chemical Society, 1997.   CL   U.S. Patent Application Serial No. 09/491,253 (11 pages).   CM   Pending claims for U.S. Application 09/980,962 (4 pages).   CN   Pending claims for U.S. Application 09/980,962 (4 pages).   CN   Pending claims for U.S. Application 09/980,962 (4 pages).			Tract", J. Aerosc	ol Medicine, 7(1):49-75, M	ary Ann Liebert, I	Iratory Inc., 1994.					
CD Edwards, D. A., et al., "Large Porous Particles for Pulmonary Drug Delivery", Science, 276:1868-1871, American Assos. Advancement Science, 1997.  CE Laube, et al., "Proving the Efficacy of Insulin Delivered Through the Lungs as an Aerosol", J. Biopharm. Sci., 3(1/2):163-169, St. Cosmas-Damian Scientific, 1992.  CF Niven, R., "Delivery of Biotherapeutics by Inhalation Aerosol", Crft. Rev. in Therapeutic Drug Carrier Systems, 12(263):151-231, Begell House, Inc., 1995.  CG Patton, J., Bukar, J., and Najarajan, S., "Inhaled insulin", Adv. Drug Delivery Rev., 35:235-247, Elsevier Science, 1999.  CH Patton, J. S. and Platz, R. M., "Aerosol Insulin- A Brief Review", Respiratory Drug Delivery IV, pages 65-74, Interpharm Press, 1994.  CI Richards, Jane P., et al., "Preparation of a Microcrystalline Suspension Formulation of LysE2BFrob29-Human Insulin with Ultralente Properties", Journal of Pharmaceutical Sciences, 88(9):861-867, American Chemical Society and American Pharmaceutical Association, September 1999.  CJ Vanbever, Rita, et al., "Sustained Release of Insulin From Insoluble Inhaled Particles", Drug Development Research 48:178-185, Wiley-Liss, Inc., 1999.  CK Whittingham, J. L., et al., "Crystal Structure of a Prolonged-Acting Insulin with Albumin-binding Properties", Biochemistry 36(10):2826-2831, American Chemical Society, 1997.  CL U.S. Patent Application Serial No. 09/491,253 (11 pages).  CM Pending claims for U.S. Application 09/958,536 (6 pages).  CN Pending claims for U.S. Application 09/958,536 (6 pages).		CC	Edwards, et al.,	. "Recent advances in p	ulmonary drug del	livery using					
Edwards, D. A., et al., "Large Porous Particles for Pulmonary Drug Delivery," Science, 276:1868-1871, American Assos. Advancement Science, 1997.  CE Laube, et al., "Proving the Efficacy of Insulin Delivered Through the Lungs as an Aerosol", J. Biopharm. Sci, 3(1/2):163-169, St. Cosmas—Damian Scientific, 1992.  CF Niven, R., "Delivery of Biotherapeutics by Inhalation Aerosol", Crit. Rev. in Therapeutic Drug Carrier Systems, 12(263):151-231, Begell House, Inc., 1995.  CG Patton, J., Bukar, J., and Najarajan, S., "Inhaled insulin", Adv. Drug Delivery Rev., 35:235-247, Elsevier Science, 1999.  CH Patton, J. S. and Platz, R. M., "Aerosol Insulin—A Brief Review", Respiratory Drug Delivery IV, pages 65-74, Interpharm Press, 1994.  CI Richards, Jane P., et al., "Preparation of a Microcrystalline Suspension Formulation of LysB28ProB29-Human Insulin with Ultralente Properties", Journal of Pharmaceutical Sciences, 88(9):861-867, American Chemical Society and American Pharmaceutical Association, September 1999.  CJ Vanhever, Rita, et al., "Sustained Release of Insulin From Insoluble Inhaled Particles", Drug Development Research 48:178-185, Wiley-Liss, Inc., 1999.  CK Whittingham, J. L., et al., "Crystal Structure of a Prolonged-Acting Insulin with Albumin-binding Properties", Biochemistry 36(10):2826-2831, American Chemical Society, 1997.  CL U.S. Patent Application Serial No. 09/491,253 (11 pages).  CM Pending claims for U.S. Application 09/980,962 (4 pages).  CM Pending claims for U.S. Application 09/988,536 (6 pages).			American Physiolo	haled particles", <i>J. Appl</i> gical Society, 1998.	. Physiol. 84(2):	379-385, the					
CE Laube, et al., "Proving the Efficacy of Insulin Delivered Through the Lungs as an Aerosol", J. Biopharm. Sci, 3(1/2):163-169, St. Cosmas-Damian Scientific, 1992.  CF Niven, R., "Delivery of Biotherapeutics by Inhalation Aerosol", Crit. Rev. in Therapeutic Drug Carrier Systems, 12(2&3):151-231, Begell House, Inc., 1995.  CG Patton, J., Bukar, J., and Najarajan, S., "Inhaled insulin", Adv. Drug Delivery Rev., 35:235-247, Elsevier Science, 1999.  CH Patton, J. S. and Platz, R. M., "Aerosol Insulin- A Brief Review", Respiratory Drug Delivery IV. pages 65-74, Interpharm Press, 1994.  CI Richards, Jane P., et al., "Preparation of a Microcrystalline Suspension Formulation of LysB28ProB29-Human Insulin with Ultralente Properties", Journal of Pharmaceutical Sciences, 869:861-867, American Chemical Society and American Pharmaceutical Association, September 1999.  CJ Vanbever, Rita, et al., "Sustained Release of Insulin From Insoluble Inhaled Particles", Drug Development Research 48:178-185, Wiley-Liss, Inc., 1999.  CK Whittingham, J. L., et al., "Crystal Structure of a Prolonged-Acting Insulin with Albumin-binding Properties", Biochemistry 36(10):2826-2831, American Chemical Society, 1997.  CL U.S. Patent Application Serial No. 09/491,253 (11 pages).  CM Pending claims for U.S. Applications 09/491,253 (11 pages).  CN Pending claims for U.S. Application 09/980,962 (4 pages).  CN Pending claims for U.S. Application 09/980,962 (4 pages).		CD	Edwards, D. A., e	et al., "Large Porous Part	icles for Pulmonar	y Drug					
CE Laube, et al., "Proving the Efficacy of Insulin Delivered Through the Lungs as an Aerosol", J. Biopharm. Sci., 3(1/2):163-169, St. Cosmas-Damian Scientific, 1992.  CF Niven, R., "Delivery of Biotherapeutics by Inhalation Aerosol", Crit. Rev. in Threapeutic Drug Carrier Systems, 12(223):151-231, Begell House, Inc., 1995.  CG Patton, J., Bukar, J., and Najarajan, S., "Inhaled insulin", Adv. Drug Delivery Rev., 35:235-247, Elsevier Science, 1999.  CH Patton, J. S. and Platz, R. M., "Aerosol Insulin- A Brief Review", Respiratory Drug Delivery IV, pages 65-74, Interpharm Press, 1994.  CI Richards, Jane P., et al., "Preparation of a Microcrystalline Suspension Formulation of LysB28ProB29-Human Insulin with Ultralente Properties", Journal of Pharmaceutical Sciences, 88(9):861-867, American Chemical Society and American Pharmaceutical Association, September 1999.  CJ Vanbever, Rita, et al., "Sustained Release of Insulin From Insoluble Inhaled Particles", Drug Development Research 48:178-185, Wiley-Liss, Inc., 1999.  CK Whittingham, J. L., et al., "Crystal Structure of a Prolonged-Acting Insulin with Albumin-binding Properties", Biochemistry 36(10):2826-2831, American Chemical Society, 1997.  CL U.S. Patent Application Serial No. 09/491,253 (11 pages).  CM Pending claims for U.S. Application 09/980,962 (4 pages).  CO Pending claims for U.S. Application 09/980,962 (4 pages).			Delivery", Science, 276:1868-1871, American Assos. Advancement Scie								
Lungs as an Aerosol", J. Biopharm. Sci, 3(1/2):163-169, St. Cosmas-Damian Scientific, 1992.  CF Niven, R., "Delivery of Biotherapeutics by Inhalation Aerosol", Crit. Rev. in Therapeutic Drug Carrier Systems, 12(2&3):151-231, Begell  CG Patton, J., Bukar, J., and Najarajan, S., "Inhaled insulin", Adv. Drug Delivery Rev., 35:235-247, Elsevier Science, 1999.  CH Patton, J. S. and Platz, R. M., "Aerosol Insulin- A Brief Review", Respiratory Drug Delivery IV, pages 65-74, Interpret Press, 1994.  CI Richards, Jane P., et al., "Preparation of a Microcrystalline Suspension Formulation of Lys828Pro829-Human Insulin with Ultralente Properties", Journal of Pharmaceutical Sciences, 89(9):861-867, American Chemical Society and American Pharmaceutical Association, September 1999.  CJ Vanbever, Rita, et al., "Sustained Release of Insulin From Insoluble Inhaled Particles", Drug Development Research 48:178-185, Wiley-Liss, Inc., 1999.  CK Whittingham, J. L., et al., "Crystal Structure of a Prolonged-Acting Insulin with Albumin-binding Properties", Biochemistry 36(10):2826-2831, American Chemical Society, 1997.  CL U.S. Patent Application Serial No. 09/491,253 (11 pages).  CM Pending claims for U.S. Application 09/980,962 (4 pages).  CN Pending claims for U.S. Application 09/980,962 (4 pages).  CN Pending claims for U.S. Application 09/958,536 (6 pages).		CE	Laube, et al., "P	roving the Efficacy of In	sulin Delivered Th	rough the					
CF   Niven, R., "Delivery of Biotherapeutics by Inhalation Aerosol", Crit. Rev. in Therapeutic Drug Carrier Systems, 12(263):151-231, Begell House, Inc., 1995.			Lungs as an Aerosol", J. Biopharm. Sci, 3(1/2):163-169. St. Cosmas-								
Rev. in Therapeutic Drug Carrier Systems, 12(2&3):151-231, Begell House, Inc., 1995.  CG Patton, J., Bukar, J., and Najarajan, S., "Inhaled insulin", Adv. Drug Delivery Rev., 35:235-247, Elsevier Science, 1999.  CH Patton, J. S. and Platz, R. M., "Aerosol Insulin A Brief Review", Respiratory Drug Delivery IV, pages 65-74, Interpharm Press, 1994.  CI Richards, Jane P., et al., "Preparation of a Microcrystalline Suspension Formulation of LysB28ProB29-Human Insulin with Ultralente Properties", Journal of Pharmaceutical Sciences, 88(9):861-867, American Chemical Society and American Pharmaceutical Association, September 1999.  CJ Vanbever, Rita, et al., "Sustained Release of Insulin From Insoluble Inhaled Particles", Drug Development Research 48:178-185, Wiley-Liss, Inc., 1999.  CK Whittingham, J. L., et al., "Crystal Structure of a Prolonged-Acting Insulin with Albumin-binding Properties", Biochemistry 36(10):2826-2831, American Chemical Society, 1997.  CL U.S. Patent Application Serial No. 09/491,253.  CM Pending claims for U.S. Applications 09/491,253 (11 pages).  CN Pending claims for U.S. Application 09/980,962 (4 pages).  CN Pending claims for U.S. Application 09/980,962 (4 pages).  CO Pending claims for U.S. Application 09/980,962 (4 pages).		CF Niven, R., "Delivery of Biotherapeutics by Inhalation Aerosol". Crit									
CG Patton, J., Bukar, J., and Najarajan, S., "Inhaled insulin", Adv. Drug Delivery Rev., 35:235-247, Elsevier Science, 1999.  CH Patton, J. S. and Platz, R. M., "Aerosol Insulin- A Brief Review", Respiratory Drug Delivery IV, pages 65-74, Interpharm Press, 1994.  CI Richards, Jane P., et al., "Preparation of a Microcrystalline Suspension Formulation of LysB28Pr629-Human Insulin with Ultralente Properties", Journal of Pharmaceutical Sciences, 88(9):861-867, American Chemical Society and American Pharmaceutical Association, September 1999.  CJ Vanbever, Rita, et al., "Sustained Release of Insulin From Insoluble Inhaled Particles", Drug Development Research 48:178-185, Wiley-Liss, Inc., 1999.  CK Whittingham, J. L., et al., "Crystal Structure of a Prolonged-Acting Insulin with Albumin-binding Properties", Biochemistry 36(10):2826-2831, American Chemical Society, 1997.  CL U.S. Patent Application Serial No. 09/491,253 (11 pages).  CM Pending claims for U.S. Applications 09/491,253 (11 pages).  CN Pending claims for U.S. Application 09/958,536 (6 pages).  CO Pending claims for U.S. Application 09/958,536 (6 pages).			Rev. in Therapeut	ic Drug Carrier Systems,	12(2&3):151-231, B	egell					
Delivery Rev., 35:235-247, Elsevier Science, 1999.  CH Patton, J. S. and Platz, R. M., "Aerosol Insulin- A Brief Review", Respiratory Drug Delivery IV. pages 65-74, Interpharm Press, 1994.  CI Richards, Jane P., et al., "Preparation of a Microcrystalline Suspension Formulation of LysB28ProB29-Human Insulin with Ultralente Properties", Journal of Pharmaceutical Sciences, 88(9):861-867, American Chemical Society and American Pharmaceutical Association, September 1999.  CJ Vanbever, Rita, et al., "Sustained Release of Insulin From Insoluble Inhaled Particles", Drug Development Research 48:178-185, Wiley-Liss, Inc., 1999.  CK Whittingham, J. L., et al., "Crystal Structure of a Prolonged-Acting Insulin with Albumin-binding Properties", Biochemistry 36(10):2826-2831, American Chemical Society, 1997.  CL U.S. Patent Application Serial No. 09/491,253.  CM Pending claims for U.S. Applications 09/491,253 (11 pages).  CN Pending claims for U.S. Application 09/980,962 (4 pages).  CO Pending claims for U.S. Application 09/958,536 (6 pages).  EXAMINER R. Tella.  DATE CONSIDERED 7/2/03  FEXAMINER: Initial if citation considered, whether or not citation is in conformance with PREP 609; Draw line through citation if not in conformance and not considered. Tralbate and the tropic of the province of the properties of the province of the province and not considered. Tralbate and the province of the province and not considered. Tralbate and the province of the province and not considered. Tralbate and the province and not considered.		CG	Patton, J., Bukar	, J., and Najarajan, S.,	"Inhaled insulin",	Adv. Drug					
CI Richards, Jane P., et al., "Preparation of a Microcrystalline Suspension Formulation of Lys828ProB29-Human Insulin with Ultralente Properties", Journal of Pharmaceutical Sciences, 88(9):861-867, American Chemical Society and American Pharmaceutical Association, September 1999.  CJ Vanbever, Rita, et al., "Sustained Release of Insulin From Insoluble Inhaled Particles", Drug Development Research 48:178-185, Wiley-Liss, Inc., 1999.  CK Whittingham, J. L., et al., "Crystal Structure of a Prolonged-Acting Insulin with Albumin-binding Properties", Biochemistry 36(10):2826-2831, American Chemical Society, 1997.  CL U.S. Patent Application Serial No. 09/491,253.  CM Pending claims for U.S. Applications 09/491,253 (11 pages).  CN Pending claims for U.S. Application 09/980,962 (4 pages).  CO Pending claims for U.S. Application 09/958,536 (6 pages).			Delivery Rev., 35	:235-247, Elsevier Science	e, 1999.	_					
CI Richards, Jane P., et al., "Preparation of a Microcrystalline Suspension Formulation of LysB28ProB29-Human Insulin with Ultralente Properties", Journal of Pharmaceutical Sciences, 88(9):861-867, American Chemical Society and American Pharmaceutical Association, September 1999.  CJ Vanbever, Rita, et al., "Sustained Release of Insulin From Insoluble Inhaled Particles", Drug Development Research 48:178-185, Wiley-Liss, Inc., 1999.  CK Whittingham, J. L., et al., "Crystal Structure of a Prolonged-Acting Insulin with Albumin-binding Properties", Biochemistry 36(10):2826-2831, American Chemical Society, 1997.  CL U.S. Patent Application Serial No. 09/491,253.  CM Pending claims for U.S. Applications 09/491,253 (11 pages).  CN Pending claims for U.S. Application 09/980,962 (4 pages).  CO Pending claims for U.S. Application 09/988,536 (6 pages).  DATE CONSIDERED 7/2/03  EXAMINER R. Initial if citation considered, whether or not citation is in conformance with 19EP 609; Draw line through citation if not in conformance and not considered. Include and the considered and not considered.		CH	Patton, J. S. and	Platz, R. M., "Aerosol In	nsulin- A Brief Re	view",					
Suspension Formulation of LysB2BProB29-Human Insulin with Ultralente Properties", Journal of Pharmaceutical Sciences, 88(9):861-867, American Chemical Society and American Pharmaceutical Association, September 1999.  CJ Vanbever, Rita, et al., "Sustained Release of Insulin From Insoluble Inhaled Particles", Drug Development Research 48:178-185, Wiley-Liss, Inc., 1999.  CK Whittingham, J. L., et al., "Crystal Structure of a Prolonged-Acting Insulin with Albumin-binding Properties", Biochemistry 36(10):2826-2831, American Chemical Society, 1997.  CL U.S. Patent Application Serial No. 09/491,253 (11 pages).  CM Pending claims for U.S. Applications 09/491,253 (11 pages).  CN Pending claims for U.S. Application 09/980,962 (4 pages).  CO Pending claims for U.S. Application 09/958,536 (6 pages).  DATE CONSIDERED 7/2/03  PEXAMINER: Initial if citation considered, whether or not citation is in conformance with 19EP 609; Draw line through citation if not in conformance and not considered. Include care		CI									
Properties", Journal of Pharmaceutical Sciences, 88(9):861-867, American Chemical Society and American Pharmaceutical Association, September 1999.  CJ Vanbever, Rita, et al., "Sustained Release of Insulin From Insoluble Inhaled Particles", Drug Development Research 48:178-185, Wiley-Liss, Inc., 1999.  CK Whittingham, J. L., et al., "Crystal Structure of a Prolonged-Acting Insulin with Albumin-binding Properties", Biochemistry 36(10):2826- 2831, American Chemical Society, 1997.  CL U.S. Patent Application Serial No. 09/491,253.  CM Pending claims for U.S. Applications 09/491,253 (11 pages).  CN Pending claims for U.S. Application 09/980,962 (4 pages).  CO Pending claims for U.S. Application 09/958,536 (6 pages).  EXAMINER  R.T. L.  DATE CONSIDERED 7/2/03  EXAMINER: Initial if citation considered, whether or not citation is in conformance with IPEP 609; Draw line through citation if not in conformance and not considered. Include convergence and not considered.			Suspension Formul	ation of LysB28ProB29-Huma	an Insulin with []]	tralente					
CJ Vanbever, Rita, et al., "Sustained Release of Insulin From Insoluble Inhaled Particles", Drug Development Research 48:178-185, Wiley-Liss, Inc., 1999.  CK Whittingham, J. L., et al., "Crystal Structure of a Prolonged-Acting Insulin with Albumin-binding Properties", Biochemistry 36(10):2826-2831, American Chemical Society, 1997.  CL U.S. Patent Application Serial No. 09/491,253.  CM Pending claims for U.S. Applications 09/491,253 (11 pages).  CN Pending claims for U.S. Application 09/980,962 (4 pages).  CO Pending claims for U.S. Application 09/958,536 (6 pages).  EXAMINER R. Tottal if citation considered, whether or not citation is in conformance with 19EP 609; Draw line through citation if not in conformance and not considered. Tackuda considered and not considered.			Properties", Jour	nal of Pharmaceutical Sci	ences, 88(9):861-8	67.					
Inhaled Particles", Drug Development Research 48:178-185, Wiley-Liss, Inc., 1999.  CK Whittingham, J. L., et al., "Crystal Structure of a Prolonged-Acting Insulin with Albumin-binding Properties", Biochemistry 36(10):2826-2831, American Chemical Society, 1997.  CL U.S. Patent Application Serial No. 09/491,253.  CM Pending claims for U.S. Applications 09/491,253 (11 pages).  CN Pending claims for U.S. Application 09/980,962 (4 pages).  CO Pending claims for U.S. Application 09/958,536 (6 pages).  EXAMINER  CX U.S. Patent Application 09/958,536 (6 pages).  DATE CONSIDERED 7/2/03  EXAMINER: Initial if citation considered, whether or not citation is in conformance with 19EP 609, Draw line through citation if not in conformance and not considered. Include ground the page of the considered of the page of			September 1999.								
CK Whittingham, J. L., et al., "Crystal Structure of a Prolonged-Acting Insulin with Albumin-binding Properties", Biochemistry 36(10):2826-2831, American Chemical Society, 1997.  CL U.S. Patent Application Serial No. 09/491,253.  CM Pending claims for U.S. Applications 09/491,253 (11 pages).  CN Pending claims for U.S. Application 09/980,962 (4 pages).  CO Pending claims for U.S. Application 09/958,536 (6 pages).  EXAMINER R.Y.    DATE CONSIDERED 7/2/03  EXAMINER: Initial if citation considered, whether or not citation is in conformance with 19EP 609; Draw line through citation if not in conformance and not considered. Include a source of the considered of the large of the considered of the large of the considered of the large of the la		CJ	Inhaled Particles", Drug Development Research 48:178-185, Wiley-Liss,								
CL U.S. Patent Application Serial No. 09/491,253.  CM Pending claims for U.S. Applications 09/491,253 (11 pages).  CN Pending claims for U.S. Application 09/980,962 (4 pages).  CO Pending claims for U.S. Application 09/958,536 (6 pages).  CO Pending claims for U.S. Application 09/958,536 (6 pages).  DATE CONSIDERED 7/2/03  PEXAMINER: Initial if citation considered, whether or not citation is in conformance with 1PEP 609; Draw line through citation if not in conformance and not considered. Include continuous considered.		CK	Whittingham, J. L	Whittingham, J. L., et al., "Crystal Structure of a Prolonged-Acting							
CL U.S. Patent Application Serial No. 09/491,253.  CM Pending claims for U.S. Applications 09/491,253 (11 pages).  CN Pending claims for U.S. Application 09/980,962 (4 pages).  CO Pending claims for U.S. Application 09/958,536 (6 pages).  EXAMINER  R. T. U. DATE CONSIDERED  7/2/03  PEXAMINER: Initial if citation considered, whether or not citation is in conformance with 1PEP 609; Draw line through citation if not in conformance and not considered. Include continuous conformance and not considered.			Insulin with Albumin-binding Properties", Biochemistry 36(10):2826-								
CN Pending claims for U.S. Application 09/980,962 (4 pages).  CO Pending claims for U.S. Application 09/958,536 (6 pages).  EXAMINER  R.T. ella  PEXAMINER: Initial if citation considered, whether or not citation is in conformance with 1PEP 609; Draw line through citation if not in conformance and not considered. Include convergence and not considered.		CL	U.S. Patent Applic	cation Serial No. 09/491,2	253.						
CN Pending claims for U.S. Application 09/980,962 (4 pages).  CO Pending claims for U.S. Application 09/958,536 (6 pages).  EXAMINER  R.T. eller  PEXAMINER: Initial if citation considered, whether or not citation is in conformance with 19EP 609; Draw line through citation if not in conformance and not considered. Include conv.		CM	Pending claims for	r U.S. Applications 09/491	.253 (11 pages)						
Pending claims for U.S. Application 09/958,536 (6 pages).  DATE CONSIDERED  7/2/03  EXAMINER: Initial if citation considered, whether or not citation is in conformance with APEP 609; Draw line through citation if not in conformance and not considered. Include good					· -						
EXAMINER  R. T. elle  DATE CONSIDERED  7/2/03  EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include some		CN	Pending claims for	r U.S. Application 09/980,	962 (4 pages).						
EXAMINER  R. T. elle  DATE CONSIDERED  7/2/03  EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include some		co	Pending claims for	r U.S. Application 09/958,	536 (6 pages).						
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include considered				,	1. []						
EXAMINER: Initial if citation considered, whether or not citation is in conformance with  MPEP 609; Draw line through citation if not in conformance and not considered. Include considered.											
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include considered			<del></del>								
EXAMINER: Initial if citation considered, whether or not citation is in conformance with  MPEP 609; Draw line through citation if not in conformance and not considered. Include considered.											
EXAMINER: Initial if citation considered, whether or not citation is in conformance with  MPEP 609; Draw line through citation if not in conformance and not considered. Include considered.											
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include considered											
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include considered											
EXAMINER: Initial if citation considered, whether or not citation is in conformance with  APEP 609; Draw line through citation if not in conformance and not considered. Include convergence and not considered.	EXAMINER			DATE CONSIDERED							
EXAMINER: Initial if citation considered, whether or not citation is in conformance with		-		7/2	7/2/03						
of this form with next communication to the applicant	*EXAMINER	Initial	if citation consider	red, whether or not citati	on is in conformar						
	of this fo	orm with	next communication to	the applicant.	ot considered. In	nclude copy					